WAM
LCTX icon

Wolverine Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Wolverine Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,850
Closed -$7K – 2576
2014
Q2 		$7K Buy
+2,850
New +$6.44K ﹤0.01% 1943

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wolverine Asset Management's LCTX Position: Q3 2014 in Review

Wolverine Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2014, closing a stake of 2,850 shares — an estimated $7K sold.

Wolverine Asset Management first reported a position in LCTX in Q2 2014 and held it in 1 quarter. The position peaked at $7K in Q2 2014. 57 funds tracked by Wall St. Rank hold LCTX as of Q3 2014.

  • Wolverine Asset Management reported no remaining Lineage Cell Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Wolverine Asset Management sold 2,850 Lineage Cell Therapeutics shares in Q3 2014, an estimated $7K.
  • Wolverine Asset Management first reported a position in Lineage Cell Therapeutics in Q2 2014 and held it in 1 quarter.
  • Wolverine Asset Management's Lineage Cell Therapeutics position peaked at $7K in Q2 2014.
  • 57 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2014.

Based on Wolverine Asset Management's 13F filing for Q3 2014, filed 13 Nov 2014.